샘플 요청 목록

 카트 문의
시장보고서
상품코드
1798908

세계의 HER2 양성 위암 시장

HER2-Positive Gastric Cancer
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 281 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

HER2 양성 위암 세계 시장은 2030년까지 3억 2,240만 달러에 달할 전망

2024년에 2억 2,210만 달러로 추정되는 HER2 양성 위암 세계 시장은 분석 기간인 2024-2030년에 CAGR 6.4%로 성장하여 2030년에는 3억 2,240만 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 화학요법은 CAGR 7.2%를 기록하며 분석 기간 종료시에는 1억 3,930만 달러에 달할 것으로 예측됩니다. 표적요법 분야의 성장률은 분석 기간 동안 CAGR 6.8%로 추정됩니다.

미국 시장은 6,050만 달러로 추정, 중국은 CAGR 10.2%로 성장 예측

미국의 HER2 양성 위암 시장은 2024년에 6,050만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간인 2024-2030년 CAGR 10.2%로 2030년까지 6,680만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 3.1%와 6.3%로 예측됩니다. 유럽에서는 독일이 CAGR 4.2%로 성장할 것으로 예측됩니다.

세계의 HER2 양성 위암 시장 - 주요 동향과 촉진요인 정리

HER2 양성은 위암 진단의 상황을 어떻게 바꿀 수 있을까?

HER2 양성 위암은 HER2(인간상피세포성장인자수용체2) 단백질의 과발현을 보이는 위암 및 위식도 접합부 암의 하위 집합을 말합니다. HER2는 일반적으로 유방암과 관련이 있지만, 위암에서 HER2의 역할은 표적치료의 예측적 가치로 인해 위암에서의 HER2의 역할이 점차 인정받고 있습니다. HER2의 상태를 정확하게 진단하는 것은 현재, 특히 진행성 및 전이성 환자에서 환자를 계층화하고 치료 요법을 안내하는 중요한 단계가 되었습니다.

HER2 양성 검사는 면역조직화학(IHC)을 통해 이루어지며, in situ hybridization(ISH) 방법으로 확인합니다. 전 세계 종양학 가이드라인에서는 HER2 표적치료의 적격성을 판단하기 위해 새로 진행성 위암 진단을 받은 환자에게 HER2 검사를 권장하고 있습니다. 이에 따라 치료 전략을 개별화하고 예후를 개선하기 위한 정밀 진단이 강조되고 있으며, 분자 프로파일링의 임상 통합이 진행되고 있습니다.

HER2 양성 위암에 대해 어떤 표적 치료제가 사용되고 있거나 개발되고 있는가?

트라스투주맙은 HER2 양성 위암 치료에 사용되는 가장 잘 알려진 표적 치료제입니다. 화학요법과 병용하면 HER2 과발현 환자의 생존율을 개선하는 것으로 나타났습니다. 위암에 대한 승인 후, HER2 표적 치료의 범위가 확대되어 항체약물접합체, 이중특이성항체, 티로신 키나아제 억제제 등 새로운 약물이 조사되고 있습니다.

트룩스투주맙, 덱스테칸 등 첨단 생물학적 제제는 1차 치료에 내성을 보이는 환자를 대상으로 임상시험이 진행되고 있으며, 임상시험에서 유효성 개선이 기대되고 있습니다. 면역요법과 HER2 표적 치료제를 통합한 병용요법도 평가 중입니다. 이러한 기술 혁신은 위암에서 HER2 발현 프로파일과 종양 특성에 따른 맞춤형 치료 파이프라인이 확대되고 있음을 반영합니다.

검사 및 치료 수요는 어디에서 성장하고 있으며, 주요 이해관계자는 누구인가?

HER2 검사와 표적 치료제의 채택은 종양센터, 대학병원, 진단연구소에서 확대되고 있습니다. 수요는 동아시아, 동유럽, 동유럽 일부, 라틴아메리카 등 위암 발병률이 높은 지역에서 가장 강합니다. 일본, 한국, 중국은 암 의료 시스템이 발달하고 검사 보급률이 높아 주요 진단 및 치료 시장이 되고 있습니다.

이해관계자에는 암 전문의, 병리검사실, 제약회사, 진단 분석 개발자가 포함됩니다. 진단 및 치료제 제조업체와 제약업체 간의 협력 관계는 동반진단 및 치료 관련 분석법 개발을 지원하고 있습니다. 국가적 암 관리 프로그램 및 공중보건 이니셔티브는 바이오마커 기반 치료 모델을 통해 암 생존율을 향상시키기 위한 광범위한 노력의 일환으로 HER2 검진을 더욱 장려하고 있습니다.

HER2 양성 위암 시장의 성장을 촉진하는 요인은 무엇일까?

HER2 양성 위암 시장의 성장은 위암 발병률 증가, 바이오마커 기반 치료 계획의 활용 증가, HER2 표적 치료 접근성 확대 등 몇 가지 요인에 기인합니다. 항체 기반 검사 및 병리 워크플로우 자동화 등 진단 정확도 향상으로 정확한 HER2 식별이 가능해졌습니다.

종양 치료 센터, 진단 연구소, 맞춤형 의약품 개발 프로그램에서의 최종 용도 확대가 시장 개척을 강화하고 있습니다. HER2 표적 생물학적 제제 파이프라인의 성장, 기존 약물의 적응증 확대, 지지적인 임상 가이드라인은 치료의 관련성을 강화하고 있습니다. 맞춤형 종양학이 계속 발전하고 있는 가운데, HER2 검사와 치료는 생물학적으로 다른 위암 환자군을 관리하는 데 있어 핵심적인 역할을 할 것으로 예상됩니다.

부문

치료 유형(화학요법, 표적요법, 면역요법, 병용요법), 최종사용자(병원 최종사용자, 전문 암센터 최종사용자, 기타 최종사용자)

조사 대상 기업 사례

  • Acepodia Biotech Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bellicum Pharmaceuticals
  • BioInvent International AB
  • Bristol-Myers Squibb
  • Carisma Therapeutics Inc.
  • Celularity Inc.
  • Daiichi Sankyo Co., Ltd.
  • Genentech(Roche Group)
  • GeneQuantum Healthcare
  • Hengrui(Jiangsu HengRui Medicine)
  • Imugene Limited
  • Klus Pharma Inc.
  • MacroGenics, Inc.
  • Merck & Co., Inc.
  • Mersana Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pieris Pharmaceuticals, Inc.
  • Shanghai Miracogen Inc.
  • Zymeworks Inc.

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계 고유의 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가가 선별한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.09.03

Global HER2-Positive Gastric Cancer Market to Reach US$322.4 Million by 2030

The global market for HER2-Positive Gastric Cancer estimated at US$222.1 Million in the year 2024, is expected to reach US$322.4 Million by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$139.3 Million by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$60.5 Million While China is Forecast to Grow at 10.2% CAGR

The HER2-Positive Gastric Cancer market in the U.S. is estimated at US$60.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$66.8 Million by the year 2030 trailing a CAGR of 10.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global HER2-Positive Gastric Cancer Market - Key Trends & Drivers Summarized

How Is HER2 Positivity Changing the Landscape of Gastric Cancer Diagnosis?

HER2-positive gastric cancer refers to a subset of gastric and gastroesophageal junction cancers that exhibit overexpression of the HER2 (Human Epidermal Growth Factor Receptor 2) protein. While HER2 is more commonly associated with breast cancer, its role in gastric cancer is gaining recognition due to its predictive value for targeted therapy. Accurate diagnosis of HER2 status is now a key step in stratifying patients and guiding treatment regimens, particularly in advanced or metastatic cases.

Testing for HER2 positivity is conducted using immunohistochemistry (IHC) and confirmed with in situ hybridization (ISH) techniques. Global oncology guidelines recommend HER2 testing in newly diagnosed advanced gastric cancer patients to determine eligibility for HER2-targeted therapy. This has led to increasing integration of molecular profiling into clinical practice, with an emphasis on precision diagnostics to personalize treatment strategies and improve prognosis.

What Targeted Therapies Are Being Used or Developed for HER2-Positive Gastric Cancer?

Trastuzumab is the most established targeted therapy used for treating HER2-positive gastric cancer. Administered in combination with chemotherapy, it has shown improved survival outcomes in patients with HER2 overexpression. Following its approval for gastric cancer, the scope of HER2-targeted treatments has expanded, with newer agents under investigation including antibody-drug conjugates, bispecific antibodies, and tyrosine kinase inhibitors.

Advanced biologics such as trastuzumab deruxtecan are being tested in patients who are resistant to first-line therapies, showing promise in clinical trials for improved efficacy. Combination therapies that integrate immunotherapy with HER2-targeted drugs are also under evaluation. These innovations reflect a growing pipeline of personalized treatments tailored to HER2 expression profiles and tumor characteristics in gastric cancers.

Where Is Demand for Testing and Treatment Growing, and Who Are the Key Stakeholders?

Adoption of HER2 testing and targeted therapy is growing across oncology centers, academic hospitals, and diagnostic laboratories. Demand is strongest in regions with high gastric cancer incidence, such as East Asia, parts of Eastern Europe, and Latin America. Japan, South Korea, and China represent major diagnostic and therapeutic markets due to well-developed cancer care systems and high testing penetration.

Stakeholders include oncologists, pathology laboratories, pharmaceutical companies, and diagnostic assay developers. Collaborations between diagnostic firms and drug manufacturers are supporting the development of companion diagnostics and therapy-linked assays. National cancer control programs and public health initiatives are further encouraging HER2 screening as part of broader efforts to improve cancer survival rates through biomarker-driven treatment models.

What Is Driving Growth in the HER2-Positive Gastric Cancer Market?

Growth in the HER2-positive gastric cancer market is driven by several factors including rising incidence of gastric cancer, increasing use of biomarker-based treatment planning, and expanding access to HER2-targeted therapies. Advances in diagnostic precision, including improved antibody-based tests and automated pathology workflows, are supporting accurate HER2 identification.

End-use expansion in oncology treatment centers, diagnostic labs, and personalized drug development programs is strengthening market adoption. Pipeline growth of HER2-directed biologics, extended indications of existing drugs, and supportive clinical guidelines are reinforcing therapeutic relevance. As personalized oncology continues to evolve, HER2 testing and therapy are expected to play a central role in managing a biologically distinct segment of gastric cancer patients.

SCOPE OF STUDY:

The report analyzes the HER2-Positive Gastric Cancer market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Combination Therapies); End-User (Hospitals End-User, Specialty Cancer Centers End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Acepodia Biotech Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bellicum Pharmaceuticals
  • BioInvent International AB
  • Bristol-Myers Squibb
  • Carisma Therapeutics Inc.
  • Celularity Inc.
  • Daiichi Sankyo Co., Ltd.
  • Genentech (Roche Group)
  • GeneQuantum Healthcare
  • Hengrui (Jiangsu HengRui Medicine)
  • Imugene Limited
  • Klus Pharma Inc.
  • MacroGenics, Inc.
  • Merck & Co., Inc.
  • Mersana Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pieris Pharmaceuticals, Inc.
  • Shanghai Miracogen Inc.
  • Zymeworks Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • HER2-Positive Gastric Cancer - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Gastric and Gastroesophageal Junction Cancers Globally Drives Demand for HER2 Biomarker Testing
    • Increased Use of Targeted Therapy in Oncology Strengthens Business Case for HER2-Directed Treatments in Gastric Cancer
    • Regulatory Approvals of HER2-Targeting Drugs Beyond Breast Cancer Propel Market Expansion in Gastric Oncology
    • Advancements in IHC and FISH-Based HER2 Diagnostics Support Early Detection and Personalized Treatment Pathways
    • Emerging Combination Therapies with HER2 Inhibitors and Immune Checkpoint Blockade Generate Innovation Momentum
    • Rising Awareness Among Oncologists About HER2-Positive Subtypes Spurs Broader Molecular Testing in GI Tumors
    • Growth in Clinical Trials Targeting HER2 Overexpression in Gastric Cancer Expands Pipeline and Treatment Options
    • Integration of HER2 Testing in Standard Diagnostic Protocols Enhances Timely Identification of Eligible Patients
    • Increasing Prevalence of HER2 Heterogeneity in Gastric Tumors Drives Research in Precision Therapy Optimization
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World HER2-Positive Gastric Cancer Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for HER2-Positive Gastric Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for HER2-Positive Gastric Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Combination Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Combination Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Combination Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Specialty Cancer Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Specialty Cancer Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Specialty Cancer Centers End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • JAPAN
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CHINA
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • EUROPE
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for HER2-Positive Gastric Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for HER2-Positive Gastric Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • FRANCE
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • GERMANY
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for HER2-Positive Gastric Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for HER2-Positive Gastric Cancer by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • INDIA
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for HER2-Positive Gastric Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for HER2-Positive Gastric Cancer by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for HER2-Positive Gastric Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for HER2-Positive Gastric Cancer by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AFRICA
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제